Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 9/20 | 0.72 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.72 |
| ▸ | IL6 | P05231 | 1/20 | 0.61 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.60 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.60 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.60 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20553091 | 0.92 | TLR7 (0.71) | TLR7NUDT1CYP2E1CYP3A4CYP2D6 | |
| SCHEMBL19369897 | 0.91 | TLR7 (0.75) | TLR7NUDT1IL6 | |
| SCHEMBL18429397 | 0.89 | TLR7 (0.75) | TLR7NUDT1IL6 | |
| SCHEMBL43878 | 0.89 | TLR7 (0.82) | TLR7NUDT1IL6 | |
| SCHEMBL12175813 | 0.89 | TLR7 (0.78) | TLR7NUDT1IL6 | |
| SCHEMBL29997135 | 0.89 | TLR7 (0.82) | TLR7NUDT1IL6 | |
| SCHEMBL19370027 | 0.88 | TLR7 (0.66) | TLR7NUDT1IL6CYP2E1CYP3A4 | |
| SCHEMBL31360530 | 0.87 | TLR7 (0.65) | TLR7NUDT1IL6 | |
| SCHEMBL14645061 | 0.87 | CYP2E1 (0.71) | TLR7NUDT1IL6CYP2E1CYP3A4 | |
| SCHEMBL18429924 | 0.86 | TLR7 (0.74) | TLR7NUDT1IL6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2903987-B1 | PHOSPHOLIPID DRUG ANALOGS | UROGEN PHARMA LTD (IL) | 2017-09-20 | — | — | EP | disclosed |
| US-9540407-B2 | Phospholipid drug analogs | UROGEN PHARMA LTD (IL) | 2017-01-10 | — | — | US | disclosed |
| US-20160090395-A1 | PHOSPHOLIPID DRUG ANALOGS | BIOPHARMA CREDIT PLC, AS COLLATERAL AGENT (GB) | 2016-03-31 | — | — | US | disclosed |
| US-9180183-B2 | Phospholipid drug analogs | TELORMEDIX SA (CH) | 2015-11-10 | — | — | US | disclosed |
| US-9180183-B2 | Phospholipid drug analogs | TELORMEDIX SA (CH) | 2015-11-10 | — | — | US | disclosed |
| US-9173936-B2 | Phospholipid drug analogs | TELORMEDIX SA (CH) | 2015-11-03 | — | — | US | disclosed |
| US-9173936-B2 | Phospholipid drug analogs | TELORMEDIX SA (CH) | 2015-11-03 | — | — | US | disclosed |
| US-9173935-B2 | Phospholipid drug analogs | TELORMEDIX SA (CH) | 2015-11-03 | — | — | US | disclosed |
| US-9173935-B2 | Phospholipid drug analogs | TELORMEDIX SA (CH) | 2015-11-03 | — | — | US | disclosed |
| US-9050319-B2 | Phospholipid drug analogs | TELORMEDIX, SA (CH) | 2015-06-09 | — | — | US | disclosed |
| US-20130267481-A1 | PHOSPHOLIPID DRUG ANALOGS | BIOPHARMA CREDIT PLC, AS COLLATERAL AGENT (GB) | 2013-10-10 | — | — | US | disclosed |
| US-20130267481-A1 | PHOSPHOLIPID DRUG ANALOGS | BIOPHARMA CREDIT PLC, AS COLLATERAL AGENT (GB) | 2013-10-10 | — | — | US | disclosed |
| US-20130266635-A1 | PHOSPHOLIPID DRUG ANALOGS | BIOPHARMA CREDIT PLC, AS COLLATERAL AGENT (GB) | 2013-10-10 | — | — | US | disclosed |
| US-20130266635-A1 | PHOSPHOLIPID DRUG ANALOGS | BIOPHARMA CREDIT PLC, AS COLLATERAL AGENT (GB) | 2013-10-10 | — | — | US | disclosed |
| US-20120009247-A1 | PHOSPHOLIPID DRUG ANALOGS | BIOPHARMA CREDIT PLC (GB) | 2012-01-12 | — | — | US | disclosed |
| US-20120009247-A1 | PHOSPHOLIPID DRUG ANALOGS | BIOPHARMA CREDIT PLC (GB) | 2012-01-12 | — | — | US | disclosed |
| US-20120003298-A1 | METHODS FOR INDUCING AN IMMUNE RESPONSE | TELORMEDIX SA (CH) | 2012-01-05 | — | — | US | disclosed |
| US-20120003298-A1 | METHODS FOR INDUCING AN IMMUNE RESPONSE | TELORMEDIX SA (CH) | 2012-01-05 | — | — | US | disclosed |
| WO-2011134669-A1 | METHODS FOR INDUCING AN IMMUNE RESPONSE | TELORMEDIX SA (CH) | 2011-11-03 | — | — | WO | disclosed |
| WO-2011134668-A1 | PHOSPHOLIPID DRUG ANALOGS | TELORMEDIX SA (CH) | 2011-11-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120003298-A1 | METHODS FOR INDUCING AN IMMUNE RESPONSE | CD4, IL4, CCR4 | TLR7 20/4885NUDT1 3462/4885IL6 1267/4885 |
| US-20130267481-A1 | PHOSPHOLIPID DRUG ANALOGS | PHOSPHO1, PXMP4, SGMS1 | TLR7 1935/4885NUDT1 1425/4885IL6 4718/4885 |
| US-20160090395-A1 | PHOSPHOLIPID DRUG ANALOGS | PHOSPHO1, PXMP4, SGMS1 | TLR7 1935/4885NUDT1 1425/4885IL6 4718/4885 |
| US-20130266635-A1 | PHOSPHOLIPID DRUG ANALOGS | PHOSPHO1, PXMP4, SGMS1 | TLR7 1935/4885NUDT1 1425/4885IL6 4718/4885 |
| US-20120009247-A1 | PHOSPHOLIPID DRUG ANALOGS | PHOSPHO1, PXMP4, SGMS1 | TLR7 1935/4885NUDT1 1425/4885IL6 4718/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.